| Entry |
|
|---|
| Name |
Amifampridine (USAN/INN);
Ruzurgi (TN) |
|---|
| Product |
|
|---|
| Formula |
C5H7N3
|
|---|
| Exact mass |
109.064
|
|---|
| Mol weight |
109.1292
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Remark |
| Product (DG02003): | D10228<US> D10689<US> |
|
|---|
| Efficacy |
Autoimmune disease treatment, Potassium channel blocker |
|---|
| Disease |
Lambert-Eaton myasthenic syndrome [DS: H01596] |
|---|
| Comment |
Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults
|
|---|
| Target |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N07 OTHER NERVOUS SYSTEM DRUGS
N07X OTHER NERVOUS SYSTEM DRUGS
N07XX Other nervous system drugs
N07XX05 Amifampridine
D10228 Amifampridine (USAN/INN) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Central Nervous System, Other
Amifampridine
D10228 Amifampridine (USAN/INN)
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Potassium channels
KCNA
D10228 Amifampridine (USAN/INN) <US>
KCNB
D10228 Amifampridine (USAN/INN) <US>
KCNC
D10228 Amifampridine (USAN/INN) <US>
KCND
D10228 Amifampridine (USAN/INN) <US>
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 8
1 C8y C 11.0600 -18.8300
2 C8x C 11.0600 -20.2300
3 N5x N 12.2724 -20.9300
4 C8x C 13.4849 -20.2300
5 C8x C 13.4849 -18.8300
6 C8y C 12.2724 -18.1300
7 N1a N 12.2724 -16.7302
8 N1a N 9.8476 -18.1300
BOND 8
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 1 8 1
|
|---|
